1. 399 Cosibelimab, an anti-PD-L1 antibody: preliminary safety and efficacy results from a global, multicohort phase 1 clinical trial. (10th December 2020) Authors: Harris, Dean; Brungs, Daniel; Ladwah, Rahul; Mant, Andrew; McGrath, Margaret; Tazbirkova, Andrea; Akopov, Andrey; Fadeeva, Natalia; Kasparov, Boris; Kovalenko, Nadezhda; Kozlov, Vadim; Moiseenko, Fedor; Oschepkov, Vasiliy; Koralewski, Piotr; Kowalski, Dariusz; Lugowska, Iwona; Charoentumn, Chaiyu... Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A242 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 399 Cosibelimab, an anti-PD-L1 antibody: preliminary safety and efficacy results from a global, multicohort phase 1 clinical trial. (9th November 2020) Authors: Harris, Dean; Brungs, Daniel; Ladwah, Rahul; Mant, Andrew; McGrath, Margaret; Tazbirkova, Andrea; Akopov, Andrey; Fadeeva, Natalia; Kasparov, Boris; Kovalenko, Nadezhda; Kozlov, Vadim; Moiseenko, Fedor; Oschepkov, Vasiliy; Koralewski, Piotr; Kowalski, Dariusz; Lugowska, Iwona; Charoentumn, Chaiyu... Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A424 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651. Issue 12 (20th April 2023) Authors: Haddad, Robert I.; Harrington, Kevin; Tahara, Makoto; Ferris, Robert L.; Gillison, Maura; Fayette, Jerome; Daste, Amaury; Koralewski, Piotr; Zurawski, Bogdan; Taberna, Miren; Saba, Nabil F.; Mak, Milena; Kawecki, Andrzej; Girotto, Gustavo; Alvarez Avitia, Miguel Angel; Even, Caroline; Toledo, Joa... Journal: Journal of clinical oncology Issue: Volume 41:Issue 12(2023) Page Start: 2166 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗